The pounds tumble under incretin-based therapies

Antiadiposita can effectively support the success of lifestyle interventions and thus close a treatment gap. In Switzerland, the GLP-1 RAs liraglutide and semaglutide are currently the most effective in the indication area of obesity. Although tirzepatide has even stronger weight-reducing effects, it is currently only approved in Germany for type 2 diabetics. Bariatric surgery is usually only considered in cases of severe obesity.